Vancomycin, safety

Breed J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E. (2005) Safety and efficacy of tigecycline in treatment of skin and skin structure infections Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49 4658 666. 

Interception of the ji-allyl palladium intermediate with soft nucleophiles such as morpholine and dimedone is attractive on the grounds of efficacy, economy, safety and scope. Deprotection of a phenol allyl ether in a synthesis of the antibiotic Vancomycin demonstrates that aryl iodides and chlorides remain intact [Scheme 4.227],429... 

Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of hnezohd as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002 50(6) 1017-26. 

Sidi V, Roilides E, Bibashi E, Gompakis N, Tsakiri A, Koliouskas D. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and Gram-positive bacteremia. J Chemother 2000 12(4) 326-31. 

Charbonneau P, Garaud J, Aubertin J, et al. Efficiency and safety of teicoplanin plus netilmicin compared to vancomycin plus netilmicin in the treatment of severe Grampositive infections. 1987 110. 

Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998 10(2) 143-52. 

In a multicenter, prospective, randomized comparison of continuous infusion of vancomycin (targeted serum plateau concentrations of 20-25 gg/ml) and intermittent infusions of vancomycin (targeted serum trough concentrations of 10-15 gg/ml) in 119 critically ill patients, microbiological and clinical outcomes and safety were similar (111). Continnous infusion of vancomycin produced the target concentration faster, and fewer samples were required for... 

Vancomycin exhibits predictable pharmacokinetic properties and its clinical use has been guided by the pharmacokinetic monitoring of serum levels to determine the dose and frequency of administration. Pharmacokinetic monitoring of vancomycin, however, has become increasingly controversial given the improved safety of this antibiotic and the lack of data to support what are considered the therapeutic and toxic serum levels. Historically, the most severe toxicities of vancomycin were ototoxicity and nephrotoxicity. The incidence of nephrotoxicity has declined since its introduction possibly due to the availability of purer forms of the antibiotic. Ototoxicity has always been a rare adverse event of vancomycin, but it has been observed with excessively high concentrations of the drug in plasma [170-172]. The purpose of this section is to describe the nephrotoxicity associated with the clinical use of vancomycin. 

Wood MJ,The comparative efficacy and safety of Teicoplanin and vancomycin, J AntimicrobChemother, 1996,37 209-22. Rehm SJ, Two new treatment options for infections due to drug-resistant gram- positive cocci, Clev Clin J Med, 2002,69(5) 397-413. 

Barriere SL. ATLAS trials efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol 2010 5(12) 1765-73. 

Long-term vancomycin therapy may induce neutropenia. A recent report of severe neutopenia following a prolonged course of vancomycin that progressed to agranulocytosis after reexposure to the dmg should be kept in mind and focus attention on the safety of rechallenging vancomycin patients with possible dmg-induced neutropenia. 

Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin systematic review and meta-analysis. Antimicrob Agents Chemother 2009 53(10) 4069-79. 

Nicolaou KC, Winssinger N, Hughes R, Smethurst C, Cho SY. New selenium-based safety-catch linkers solid-phase semisynthesis of vancomycin. Angew. Chem. Int. Ed. 2000 39 1084-1088. 

---